# Restrictive Lung Disease

Confirm true restriction with total lung capacity, then separate intrinsic parenchymal disease from obesity, neuromuscular, chest-wall, and pleural causes using diffusion capacity, imaging, oxygenation, and targeted etiologic testing.

**Clinical question:** How should clinicians confirm, classify, and evaluate restrictive lung disease while identifying patients who require ILD-center referral or transplant assessment?

Updated: 2026-08-24T18:21:05.118307+00:00

## What matters in practice
- Do not diagnose restriction from spirometry alone; establish true restriction with reduced total lung capacity and then interpret DLCO with imaging and the clinical context. [11][12][18]
- A reduced TLC with reduced DLCO favors intrinsic parenchymal disease, whereas obesity, chest-wall disorders, and neuromuscular weakness can produce extrapulmonary restriction with different physiologic patterns. [11][12]
- For suspected ILD, obtain complete PFTs including hemoglobin-corrected DLCO, resting and exertional oxygenation, and a baseline 6-minute walk test; use HRCT to define the radiologic pattern and extent. [6][7][20]
- When noninvasive evaluation does not establish a confident ILD diagnosis, refer for multidisciplinary discussion; transbronchial cryobiopsy is an option at experienced ILD centers, while surgical biopsy remains relevant when pathology will change management. [6][12][13]
- Consider early lung-transplant referral in progressive fibrosing ILD; listing consideration includes declining FVC below 80% predicted, DLCO below 40% predicted, declining or less than 250-m 6-minute walk distance, or acute exacerbation. [6]

## Confirm restriction before assigning an ILD diagnosis

Reduced FVC is not synonymous with restrictive lung disease.

Confirm restriction with full lung volumes: a restrictive ventilatory defect is defined physiologically by reduced total lung capacity (TLC). Spirometry may show reduced FVC, but reduced FVC alone can reflect poor effort, airflow obstruction with air trapping, or extrapulmonary mechanical limitation; obtain plethysmographic lung volumes when feasible. [7][11][12][18]

Order DLCO, corrected for hemoglobin where feasible, with spirometry and lung volumes. In intrinsic parenchymal restriction, reduced TLC commonly accompanies impaired diffusion capacity; integrate DLCO with HRCT rather than using it as a stand-alone etiologic test. [7][11][12][18]

Obtain resting pulse oximetry and an exertional assessment, preferably a 6-minute walk test (6MWT), at baseline when ILD is suspected. The 6MWT supplies oxygenation and functional data that complement resting PFTs and should be repeated for disease monitoring when clinically indicated. [6][7][20]
- Reduced TLC plus reduced DLCO: prioritize intrinsic lung disease, especially fibrosing or inflammatory ILD, while assessing for pulmonary vascular and emphysema-related contributions to reduced diffusion capacity. [11][12][18]
- Reduced TLC with obesity: obesity commonly produces an isolated reduction in expiratory reserve volume (ERV); do not attribute marked diffusion impairment or fibrotic HRCT abnormalities to obesity alone. [12]
- Reduced TLC and vital capacity with preserved residual volume: consider neuromuscular weakness; assess for diaphragmatic, motor neuron, myopathic, or other neuromuscular disease before labeling the patient as having ILD. [12]
- Reduced TLC with chest-wall or pleural abnormality: use chest imaging and examination to identify kyphoscoliosis, pleural pathology, or other extrapulmonary mechanical restriction. [11][12]

*Physiologic patterns that redirect the restrictive-lung-disease differential. [11][12][18]*

| Pattern | Interpretation | Next action |
| --- | --- | --- |
| Reduced FVC without documented low TLC | Restriction is unconfirmed; spirometry alone is insufficient. [11][12] | Obtain lung volumes, ideally plethysmography, and DLCO. [7][12] |
| Reduced TLC plus low DLCO | Supports intrinsic parenchymal restriction when concordant with imaging and clinical findings. [11][12][18] | Obtain HRCT and pursue a structured ILD evaluation. [11] |
| Reduced TLC with isolated low ERV in obesity | Pattern may reflect obesity-related mechanical limitation. [12] | Assess for a second process if DLCO is reduced, hypoxemia is disproportionate, or imaging is abnormal. [12] |
| Reduced TLC and VC with preserved RV | Raises concern for neuromuscular weakness. [12] | Evaluate neuromuscular and diaphragmatic causes rather than assuming intrinsic lung fibrosis. [12] |
| Reduced TLC with chest-wall or pleural abnormality | Suggests extrapulmonary restriction. [11][12] | Define the structural cause with imaging and direct management to the chest-wall or pleural disorder. [11][12] |

## Use HRCT and exposure-directed testing to classify intrinsic restriction

The highest-yield distinction is intrinsic ILD versus extrapulmonary restriction.

For confirmed or strongly suspected intrinsic restriction, obtain high-resolution CT (HRCT) of the chest and compare with prior imaging. In IPF, HRCT can show basal and posterior-predominant reticulation early and peripheral/subpleural honeycombing with traction bronchiectasis in advanced disease; imaging pattern and distribution direct the next diagnostic branch. [11]

Take a structured exposure and medication history before classifying fibrosis as idiopathic: document cigarette exposure, environmental and occupational exposures, medication exposure, family history, and timing of symptoms relative to these risks. These exposures are routinely captured in IPF evaluation because they can identify an alternative cause of fibrosing lung disease. [20]

If connective-tissue disease is plausible clinically, obtain targeted autoimmune testing and assess for systemic features rather than relying on pulmonary physiology alone. CTD-related ILD assessment is complicated by extrapulmonary comorbidities that can confound measures of pulmonary activity and severity; interpret dyspnea, walk limitation, and PFT change in that context. [3][11]
- UIP-pattern fibrosis in an appropriate clinical setting may permit diagnosis through integrated history, HRCT, and exclusion of alternatives without lung biopsy. [12]
- A nonspecific interstitial pneumonia pattern requires exclusion of secondary causes; pathology, when obtained, shows temporally homogeneous inflammatory and fibrosing interstitial disease and lacks the fibroblastic foci and peripheral accentuation typical of UIP. [13]
- Fibrotic ILD cohorts commonly include CTD-ILD, fibrotic hypersensitivity pneumonitis, and non-IPF idiopathic interstitial pneumonia; do not treat progressive fibrosis as a single disease until the etiologic workup is complete. [23][24]
- Incidental bilateral nondependent ground-glass opacity, reticulation, architectural distortion, traction bronchiectasis, honeycombing, or nonemphysematous cysts involving at least 5% of a lung zone meets the radiologic definition of an interstitial lung abnormality (ILA); determine whether symptoms, physiology, or a specific ILD pattern instead establish clinical ILD. [10]

### When HRCT does not settle the diagnosis

Refer cases with discordant clinical, radiologic, and pathologic findings—or persistent diagnostic uncertainty after comprehensive noninvasive evaluation—to an ILD multidisciplinary discussion involving pulmonology, thoracic radiology, and pathology. Interdisciplinary discussion is the diagnostic reference standard for ILD and is specifically recommended when HRCT and histology are nondiagnostic or discordant. [6][2]

Select tissue sampling only if it is expected to change diagnostic confidence or management. Surgical lung biopsy is considered when IPF cannot be confirmed noninvasively and clinical-radiologic findings are incongruent with UIP, provided procedural risk is acceptable. Traditional transbronchial forceps biopsies have low yield for diffuse ILD; cryobiopsy may be used at experienced ILD centers, with an approximately 70% to 80% diagnostic yield and lower procedural risk than video-assisted thoracoscopic surgery. [6][12][13]
- For surgical biopsy or cryobiopsy, obtain specimens from more than one lobe when tissue diagnosis is pursued for diffuse ILD. [13]
- Avoid biopsy when the expected diagnostic gain is unlikely to outweigh procedural risk or when a confident multidisciplinary diagnosis can be made noninvasively. [12]

*Actionable etiologic branches after confirmed intrinsic restrictive physiology. [3][10][11][12][13][20][23][24]*

| Clinical-radiologic branch | Discriminators | Next diagnostic step |
| --- | --- | --- |
| Idiopathic pulmonary fibrosis/UIP consideration | Older adult with unexplained bilateral fibrosis, bibasilar crackles, restrictive physiology, and HRCT showing basal-posterior and peripheral/subpleural fibrotic change, honeycombing, or traction bronchiectasis. [11][12] | Exclude alternative causes; use multidisciplinary review and consider biopsy only if HRCT-clinical integration is not diagnostic. [6][12] |
| CTD-associated ILD | Systemic CTD features or targeted autoantibody findings with compatible ILD; nonpulmonary comorbidities can confound severity assessment. [3][11] | Integrate rheumatologic assessment, HRCT, PFT trajectory, and oxygenation rather than interpreting dyspnea alone. [3][7] |
| Fibrotic hypersensitivity pneumonitis or exposure-related ILD | Relevant environmental, occupational, or drug exposure temporally linked to lung disease. [20][23] | Identify and remove the implicated exposure and use HRCT plus multidisciplinary assessment to establish the ILD subtype. [6][20][23] |
| NSIP | Diagnosis of exclusion; pathology shows temporally homogeneous inflammation and fibrosis without UIP-type fibroblastic foci or peripheral accentuation. [13] | Search for secondary causes, particularly CTD, before calling NSIP idiopathic. [13] |
| Interstitial lung abnormality | Incidental bilateral nondependent interstitial abnormality involving at least 5% of a lung zone, with or without fibrotic features. [10] | Compare prior imaging, classify fibrotic versus nonfibrotic ILA, and determine whether symptoms, impaired physiology, or a defined ILD diagnosis reclassify the patient as clinical ILD. [10] |

## Measure physiologic decline and identify advanced fibrosing disease early

Use serial function, exertional oxygenation, and imaging—not symptoms alone—to determine progression.

Establish a baseline that includes FVC, TLC, hemoglobin-corrected DLCO, resting oxygen saturation, and 6MWT. Serial change in FVC and DLCO, worsening exertional oxygenation, declining 6MWT distance, and interval HRCT progression provide complementary evidence of progressive fibrosing disease; symptoms may be confounded by cardiac, musculoskeletal, rheumatologic, or other comorbid conditions. [3][6][7][20]

Assess for acute clinical deterioration promptly in established IPF or fibrosing ILD. A commonly used acute-exacerbation framework includes deterioration within 30 days, new bilateral ground-glass opacities or consolidation superimposed on a reticular or honeycomb UIP background, and exclusion of pulmonary infection and alternative causes of acute worsening. [19]

Refer early for lung-transplant evaluation in IPF and other progressive ILD rather than waiting for end-stage respiratory failure. Listing consideration includes FVC below 80% predicted with decline, DLCO below 40% predicted, 6MWT distance below 250 m or declining, or an acute ILD exacerbation. [6]
- Use the 6MWT to document exercise capacity and oxygenation at baseline and during follow-up; oximetry is important for ILD prognostication and monitoring. [6][7]
- Interpret a disproportionately low DLCO in the full cardiopulmonary context; trial eligibility criteria used an FVC-percent-predicted to DLCO-percent-predicted ratio of 1.8 or greater as a trigger to exclude pulmonary hypertension by right-heart catheterization. [17]
- CT disease extent is prognostically informative in IPF; visually determined extent on CT is an independent predictor in physiologic-prognostic assessment. [21]

*Findings that should trigger escalation in fibrosing ILD. [6][17][19][21]*

| Finding | Interpretation | Immediate next step |
| --- | --- | --- |
| FVC below 80% predicted and declining | Supports transplant-listing consideration in ILD. [6] | Refer or re-engage a lung-transplant program while continuing ILD-directed management. [6] |
| DLCO below 40% predicted | Advanced physiologic impairment supporting transplant-listing consideration. [6] | Assess oxygenation, comorbid pulmonary hypertension, and transplant candidacy. [6][17] |
| 6MWT below 250 m or declining | Functional decline supporting transplant-listing consideration. [6] | Reassess exertional oxygenation and refer for transplant evaluation if not already completed. [6] |
| Acute worsening within 30 days with new bilateral ground-glass opacity or consolidation | Raises concern for acute exacerbation after infection and alternative causes are excluded. [19] | Urgently evaluate oxygenation, infection, and competing cardiopulmonary causes. [19] |
| FVC-percent-predicted/DLCO-percent-predicted ratio at least 1.8 | May indicate a need to evaluate for pulmonary hypertension in an appropriate clinical context. [17] | Consider right-heart catheterization when pulmonary hypertension assessment will alter management. [17] |

## Direct management to the confirmed mechanism and severity trajectory

Restriction is a physiologic pattern; treatment follows the cause rather than the PFT label.

For extrapulmonary restriction, manage the identified mechanical or neuromuscular driver rather than initiating ILD-directed therapy. Obesity-associated physiology often includes isolated ERV reduction, whereas neuromuscular disease can produce low TLC and vital capacity with preserved residual volume; chest-wall and pleural disorders require structural characterization on examination and imaging. [11][12]

For fibrosing ILD, establish the disease subtype through HRCT, exposure review, autoimmune assessment, and multidisciplinary interpretation before selecting disease-directed treatment. Antifibrotic therapy with nintedanib or pirfenidone slows lung-function decline in progressive fibrosing ILD, but agent selection, labeling status, contraindications, and dosing require confirmation against current prescribing information and the specific ILD diagnosis. [22]

Provide oxygen when clinically indicated by resting or exertional hypoxemia and incorporate pulmonary function, oxygenation, and 6MWT into longitudinal management. For progressive disease, transplant referral is not a last-resort intervention: early referral is recommended at IPF diagnosis because wait-list time can limit access to transplantation. [6][22]
- Do not classify a patient as idiopathic until medication, environmental, occupational, smoking, family-history, and CTD branches have been considered. [20][23]
- Avoid reflex immunosuppression based on a restrictive PFT pattern; distinguish UIP/IPF, CTD-ILD, fibrotic hypersensitivity pneumonitis, NSIP, and extrapulmonary restriction first. [12][13][23][24]
- At each clinically meaningful reassessment, document FVC, DLCO, oxygenation, exertional capacity, symptoms, adverse events, and interval imaging when progression is uncertain or treatment decisions depend on radiographic change. [6][7][20]

*Cause-directed management priorities in restrictive lung disease. [6][11][12][20][22][23][24]*

| Confirmed category | Management priority | Monitoring focus |
| --- | --- | --- |
| Obesity, chest-wall, pleural, or neuromuscular restriction | Treat the extrapulmonary mechanical or neuromuscular disorder; do not use an ILD pathway without corroborating imaging or diffusion impairment. [11][12] | TLC, VC/FVC, symptoms, and the underlying disorder's trajectory. [12] |
| IPF or progressive fibrosing ILD | Consider antifibrotic therapy with nintedanib or pirfenidone and assess early transplant referral. [6][22] | FVC, DLCO, oxygenation, 6MWT, HRCT progression, and acute exacerbations. [6][20] |
| CTD-ILD | Coordinate pulmonary and systemic disease assessment because nonpulmonary comorbidity may confound severity measures. [3] | PFT trend, oxygenation, HRCT, and CTD activity or comorbidity burden. [3][7] |
| Exposure-related fibrosing ILD | Identify and remove relevant environmental, occupational, or drug exposure while confirming subtype through integrated assessment. [20][23] | Symptoms, PFTs, oxygenation, and radiographic progression after exposure intervention. [7][20] |

## References
1. Progressive fibrosing interstitial lung disease: clinical ... — www.thelancet.com — https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30355-6/abstract
2. Multicentre evaluation of multidisciplinary team meeting ... — www.thelancet.com — https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(16)30033-9/fulltext
3. Connective tissue disease related interstitial lung ... - Thorax — thorax.bmj.com — https://thorax.bmj.com/content/69/5/436
4. from childhood to adult interstitial lung disease — thorax.bmj.com — https://thorax.bmj.com/content/79/12/1162
5. Machine learning in radiology: the new frontier in interstitial ... — www.thelancet.com — https://www.thelancet.com/journals/landig/article/PIIS2589-7500(22)00230-8/fulltext
6. Interstitial Lung Disease - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK541084
7. Management of Interstitial Lung Diseases: A consensus statement of the Indian Chest Society (ICS) and National College of Chest Physicians (NCCP ) — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC7507933
8. Clinical care in interstitial lung disease: a critical appraisal of clinical guidance documents — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12648271
9. Update in diagnosis and management of interstitial lung disease — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC6297625
10. Current diagnosis, epidemiology, and management of interstitial lung abnormalities — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12916703
11. Restrictive Lung Disease - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK560880
12. Idiopathic Pulmonary Fibrosis - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK448162
13. Nonspecific Interstitial Pneumonia - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK518974
14. Using Bronchoscopic Lung Cryobiopsy and a Genomic ... — journal.chestnet.org — https://journal.chestnet.org/article/S0012-3692(20)31499-9/pdf
15. Online Supplement — journal.chestnet.org — https://journal.chestnet.org/cms/10.1016/j.chest.2021.03.066/attachment/e1215f3c-b627-48df-8920-42145789a2e2/mmc1.pdf
16. d7811c00001-sap-ed-2_8Aug2024_Redacted — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/14/NCT05246514/SAP_001.pdf
17. Clinical Trial Protocol — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/45/NCT02745145/Prot_000.pdf
18. Pulmonary Function Tests for the Radiologist — pubs.rsna.org — https://pubs.rsna.org/doi/abs/10.1148/rg.2017160174
19. [PDF] Galactic-1 Study Protocol - Clinical Trials — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/46/NCT03832946/Prot_000.pdf
20. '-1lll1v Ingelheim — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/80/NCT02803580/Prot_001.pdf
21. Idiopathic Pulmonary Fibrosis: Physiologic Tests ... — pubs.rsna.org — https://pubs.rsna.org/doi/abs/10.1148/radiol.2463062200
22. Management of Progressive Fibrosing Interstitial Lung ... — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/34722582
23. Study Details | NCT06855329 | PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis | ClinicalTrials.gov — clinicaltrials.gov — https://clinicaltrials.gov/study/NCT06855329
24. Study Details | NCT06416163 | FIBRotic Interstitial Lung Disease With Nocturnal hypOXaemia and EXercise Induced desaTuRAtion | ClinicalTrials.gov — clinicaltrials.gov — https://clinicaltrials.gov/study/NCT06416163

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.